MedTrace Logo

Spectroscopy in Parkinson Disease

NCT01005030 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2009-11-10

No results posted yet for this study

Summary

The primary objective of the study is to determine the utility of blood plasma infrared spectroscopy (biospectroscopy) in distinguishing subjects with idiopathic Parkinson's disease from healthy controls.

Conditions

  • Parkinson Disease

Interventions

OTHER

Blood draw

Blood draw, two tubes, used for isolation of cell-free blood plasma

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • Molecular Biometrics, Inc.

    lead INDUSTRY

Principal Investigators

  • Bernard Ravina, MD · University of Rochester

  • Anthony E Lang, MD · University of Toronto

Eligibility

Min Age
46 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2013-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01005030 on ClinicalTrials.gov